Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Immatics NV (IMTX)

Immatics NV (IMTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,017,589
  • Shares Outstanding, K 84,658
  • Annual Sales, $ 58,440 K
  • Annual Income, $ -104,980 K
  • 60-Month Beta 0.75
  • Price/Sales 16.83
  • Price/Cash Flow N/A
  • Price/Book 2.26
Trade IMTX with:

Options Overview Details

View History
  • Implied Volatility 37.94% ( -17.25%)
  • Historical Volatility 69.27%
  • IV Percentile 1%
  • IV Rank 2.87%
  • IV High 183.85% on 10/20/23
  • IV Low 33.63% on 06/25/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 231
  • Put/Call OI Ratio 1.18
  • Today's Open Interest 12,043
  • Open Int (30-Day) 11,619

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.35
  • Number of Estimates 2
  • High Estimate -0.34
  • Low Estimate -0.36
  • Prior Year -0.35
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.97 +9.57%
on 06/03/24
13.77 -12.71%
on 06/06/24
+0.99 (+8.98%)
since 05/31/24
3-Month
9.67 +24.30%
on 04/25/24
13.77 -12.71%
on 06/06/24
+1.29 (+12.02%)
since 04/02/24
52-Week
7.15 +68.11%
on 10/31/23
13.77 -12.71%
on 06/06/24
+0.48 (+4.16%)
since 06/30/23

Most Recent Stories

More News
Immatics: Q1 Earnings Snapshot

Immatics: Q1 Earnings Snapshot

IMTX : 12.02 (+0.17%)
Immatics: Q3 Earnings Snapshot

Immatics: Q3 Earnings Snapshot

IMTX : 12.02 (+0.17%)
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

/PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

IMTX : 12.02 (+0.17%)
PLX : 1.1200 (-4.27%)
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules

MRNA : 117.07 (+0.97%)
IMTX : 12.02 (+0.17%)
Immatics: Q2 Earnings Snapshot

Immatics: Q2 Earnings Snapshot

IMTX : 12.02 (+0.17%)
Immatics: Q1 Earnings Snapshot

Immatics: Q1 Earnings Snapshot

IMTX : 12.02 (+0.17%)
Why Immatics Stock Is Soaring Today

Investors liked what they heard in Immatics' interim results for experimental immunotherapy IMA203.

IMTX : 12.02 (+0.17%)
Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases

Seamless Therapeutics today announced a $12.5 million (€11.8M) seed financing round which will accelerate further development of its designer recombinases, a novel gene editing platform to transform...

IMTX : 12.02 (+0.17%)
Immatics: Q3 Earnings Snapshot

Immatics: Q3 Earnings Snapshot

IMTX : 12.02 (+0.17%)
Immatics Announces Second Quarter 2022 Financial Results and Business Update

ACTengine® TCR-T cell therapy targeting PRAME is enrolling patients in all three Phase 1b cohorts: IMA203 monotherapy at provisional recommended Phase 2...

IMTX : 12.02 (+0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Immatics N.V. engages in the discovery of targets for cancer immunotherapies. It is developing targeted immunotherapies with focus on treating solid tumors. Immatics N.V., formerly known as ARYA SCIENCES, is based in Tuebingen, Germany.

See More

Key Turning Points

3rd Resistance Point 12.55
2nd Resistance Point 12.30
1st Resistance Point 12.16
Last Price 12.02
1st Support Level 11.77
2nd Support Level 11.52
3rd Support Level 11.38

See More

52-Week High 13.77
Last Price 12.02
Fibonacci 61.8% 11.24
Fibonacci 50% 10.46
Fibonacci 38.2% 9.68
52-Week Low 7.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar